Thiacetazone and Its Effect on Mycolic Acids in Mycobacteria
Author Information
Author(s): Alahari Anuradha, Trivelli Xavier, Guérardel Yann, Dover Lynn G., Besra Gurdyal S., Sacchettini James C., Reynolds Robert C., Coxon Geoffrey D., Kremer Laurent
Primary Institution: Laboratoire de Dynamique des Interactions Membranaires Normales et Pathologiques, Université de Montpellier II et I, Centre National de la Recherche Scientifique (CNRS), UMR 5235, Montpellier, France
Hypothesis
Does thiacetazone inhibit the cyclopropanation of mycolic acids in mycobacteria?
Conclusion
Thiacetazone inhibits the cyclopropanation of mycolic acids in mycobacteria, revealing CMASs as its cellular targets.
Supporting Evidence
- Thiacetazone and its analogues were shown to inhibit mycolic acid cyclopropanation.
- Significant changes in mycolic acid profiles were observed in treated mycobacterial strains.
- Overexpression of CMAS genes partially reversed the effects of thiacetazone.
Takeaway
Thiacetazone is a drug that helps fight tuberculosis by stopping bacteria from making important parts of their cell walls.
Methodology
The study used thin layer chromatography, mass spectrometry, and NMR analyses to assess the effects of thiacetazone on mycolic acid synthesis.
Limitations
The study does not explore the effects of thiacetazone on all possible mycobacterial strains.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website